The European Medicines Agency's CHMP has recommended approval of Sanofi's Cenrifki (tolebrutinib) for treating secondary progressive multiple sclerosis (SPMS) without relapses in the last two years. This recommendation is based on the HERCULES phase 3 study showing Cenrifki significantly delays disability progression in non-relapsing SPMS patients. Cenrifki targets neuroinflammation, addressing a major unmet need in MS treatment. A final EU decision is expected in the coming months, with further regulatory reviews ongoing worldwide.
The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...
Paulo Fontoura has resigned from the Board of Directors at Lakefront Biotherapeutics following his appointment as Executive Vice President and Global Head of Research & Development Pharma at Sanofi. Lakefront's board chair congratulated Fontoura and ...
